A Phase II, Multicenter, Single-Arm, Two-Cohort Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Patients With Advanced Basal Cell Carcinoma.

Trial Profile

A Phase II, Multicenter, Single-Arm, Two-Cohort Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Patients With Advanced Basal Cell Carcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs Vismodegib (Primary)
  • Indications Basal cell cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ERIVANCE BCC
  • Sponsors Genentech
  • Most Recent Events

    • 12 Oct 2017 Results mapping the SF-36 data onto EQ-5D utilities for use in health economic evaluations, presented at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
    • 02 Aug 2017 Results of pooled retrospective analysis of this and other 3 studies published in the Journal of the American Academy of Dermatology.
    • 25 May 2016 Results assessing effectiveness of the two drugs using a matching-adjusted indirect comparison from BOLT and ERIVANCE trials presented at the 21st Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top